|
Daily Medical Update
Adrenal Incidentaloma (Workup, surveillance)
Monday, March 30, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
The Lancet Diabetes & Endocrinology (2025) - Randomized Controlled Trial
Key Findings
- Reduction of antihypertensive treatment with normal home BP occurred in 46% after adrenalectomy vs 15% with conservative care (adjusted RD 0.34, 95% confidence interval 0.11-0.58; p=0.0038).
- At study completion, ongoing antihypertensive treatment was needed in 43% after adrenalectomy vs 96% with conservative management, with a 2.05-step lower mean treatment intensity (p<0.0001).
📋 Practice Implication: For patients with unilateral incidentaloma plus MACS and difficult hypertension, endocrine/surgical referral is justified because adrenalectomy can materially reduce medication burden and improve BP targets.
|
European Journal of Endocrinology (2026) - Prospective Cohort
Key Findings
- MACS was associated with greater baseline cardiac remodeling vs NFAI, including LV hypertrophy 46% vs 16% and higher LV mass index (100 vs 85 g/m²; p=0.011).
- LV mass index improved at 1 year after adrenalectomy (-14.8 g/m²) but worsened with surveillance (+13.7 g/m²), and by 5 years trajectories converged while NFAI increased by +22.4 g/m² (p<0.001).
📋 Practice Implication: Even after initial treatment decisions, MACS patients should remain on structured long-term cardiovascular follow-up, because cardiac remodeling can recur and risk does not disappear after short-term improvement.
|
The Journal of Clinical Endocrinology & Metabolism (2026) - Systematic Review and Meta-analysis
Key Findings
- Compared with controls, nonfunctioning incidentaloma cohorts showed increased cIMT (SMD 1.22) and insulin resistance (SMD 0.51), indicating higher cardiometabolic burden.
- Additional adverse vascular markers increased vs controls, including AIx (SMD 0.94), PWV (SMD 1.03), and LV mass index (SMD 0.41), while endothelial function decreased (FMD SMD -1.24).
📋 Practice Implication: Do not treat nonfunctioning incidentaloma as a benign endpoint; integrate proactive risk-factor management (BP, glycemia, lipids, weight) into routine primary care surveillance.
|
|
Recent evidence supports a risk-stratified adrenal incidentaloma workflow: in unilateral MACS with hypertension, adrenalectomy improves blood-pressure control versus conservative care, while cardiometabolic and cardiac remodeling risks persist even in ostensibly nonfunctioning disease. For PCP practice, early endocrine phenotyping and longitudinal cardiometabolic surveillance remain central, with selective use of evolving imaging/risk tools to reduce unnecessary downstream testing.
|
|